Abstract Number: 1750 • ACR Convergence 2024
Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study
Background/Purpose: Systemic autoimmune diseases are based on an aberrant activation of B cells. Autologous CD19 chimeric antigen receptor (CAR) T cells allow deep depletion of…Abstract Number: 1834 • ACR Convergence 2024
Altered Mechanotransduction via Myosin II Contributes to Collagen and IL-6 Production in Systemic Sclerosis Skin
Background/Purpose: Scleroderma (SSc), an autoimmune disease, features progressive fibrosis, leading to significant morbidity and mortality. Current therapies manage symptoms but lack efficacy in directly targeting…Abstract Number: 2455 • ACR Convergence 2024
Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a systemic autoimmune disease characterized by vasculopathy and multiorgan fibrosis leading to significant morbidity and early mortality. Autologous stem…Abstract Number: 2643 • ACR Convergence 2024
Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc). TGFβ is a key growth factor driving myofibroblast formation in SSc. The main…Abstract Number: 0618 • ACR Convergence 2023
Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…Abstract Number: 0636 • ACR Convergence 2023
Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing
Background/Purpose: Pain is a prominent symptom in numerous rheumatological diseases. In order to allow for a standardized quantification and the assessment of nociceptive and non-nociceptive…Abstract Number: 0658 • ACR Convergence 2023
Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis
Background/Purpose: The gastrointestinal (GI) tract is the second most commonly impacted organ in systemic sclerosis (SSc). However, the pathogenesis and clinical expression of GI involvement…Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…Abstract Number: 0954 • ACR Convergence 2023
Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with vasculopathy, inflammation, and fibrosis of the skin and organs. Fibrosis is caused by the abnormal…Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…Abstract Number: 1704 • ACR Convergence 2023
Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…Abstract Number: 2366 • ACR Convergence 2023
Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…Abstract Number: 0619 • ACR Convergence 2023
Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review
Background/Purpose: There is no established consensus on defining the clinical course and the outcomes of systemic sclerosis-associated interstitial lung disease (SSc-ILD), both among experts and…Abstract Number: 0637 • ACR Convergence 2023
Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort
Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…Abstract Number: 0659 • ACR Convergence 2023
Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort
Background/Purpose: In rheumatoid arthritis, cigarette smoking confers a risk for anti-CCP positive disease and the risk further increases in smokers carrying specific HLA DRB1-variants. These…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 46
- Next Page »